Objective: Preeclampsia (PE) is a
disease that characterized by hypertension and proteinuria during pregnancy.
Epoxyeicosatrienoic acids (EETs) are arachidonic acid metabolites which have
vasodilatator, anti-inflammatory and profibrinolytic effects. Soluble epoxide
hydrolase (sEH; EC 3.3.3.2) catalyses the degradation of EETs to their inactive
diols (DHETs). Low circulating levels of EETs may be related to high blood
pressure in preeclampsia. The aim of this study is to determine the level of
11,12-DHETs, a representative metabolite of sEH-mediated metabolism of EET, in
preeclamptic patients.
Method: 11,12-DHET levels were
measured by ELISA in plasma samples of 75 PE patients and 75 normotensive
pregnant women as controls.
Results: It was found that lasma
11,12-DHET levels of PE patients was significantly increased compared to the
control group (p <0.05).
Conclusions: These results and our
previous findings suggest that high sEH activities in PE patients may cause to
produce more 11,12-DHETs in PE. sEH enzyme with high catalytic activity may
play a role in the pathogenesis of PE by contributing to the reduction of
vasodilatator, anti-hypertensive and anti-inflammatory effects of EETs by rapid
degradation of these molecules.
Dihydroxy-eicosatrienoic acid Epoxyeicosatrienoic acid Preeclampsia Soluble epoxide hydrolase
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Surgical Science Research Articles |
Authors | |
Publication Date | December 29, 2018 |
Acceptance Date | December 28, 2018 |
Published in Issue | Year 2018 |